Skip to main content
Premium Trial:

Request an Annual Quote

Elixir Pharmaceuticals Closes Merger, $17 Million VC Funding



NEW YORK, February 12 -- Centagenetix and Elixir Pharmaceuticals today announced the completion of a merger initiated in January and a $17 million injection of venture capital.


The new company, called Elixir Pharmaceuticals, will be based in Cambridge, Mass., and led by Edward Cannon, president and CEO. The merger was an all-stock transaction.


Elixir is creating a technology platform for drug discovery targeting aging in laboratory organisms, while Centagenetix has a portfolio of population association studies of genes and gene variants from individuals of extreme longevity and vitality.


The new company will receive venture funding through the initial closing of a $17 million Series B round of financing led by MPM Capital of Boston, LP Arch Venture Partners of Chicago, and Oxford Bioscience Partners of Boston. 


The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.